A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

NCT06424899 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Adebrelimab
RADIATION: radical chemoradiotherapy
DRUG: Platinum based chemotherapy

Sponsor

Zeng Jian